Lunai Bioworks (LNAI) Change in Accured Expenses (2012 - 2026)
Lunai Bioworks (LNAI) recorded quarterly Change in Accured Expenses of -$30857.0 in Q1 2026, down 134.85% quarter-over-quarter from $88541.0 in Q4 2025, and down 3085800.0% on a YoY basis from N/an in Q1 2025.
Lunai Bioworks (LNAI) Change in Accured Expenses (2012 - 2026) Analysis & Trends
Lunai Bioworks' Change in Accured Expenses history runs 15 years deep, the most recent figure standing at -$30857.0 for Q1 2026.
- In Q1 2026, Change in Accured Expenses fell 3085800.0% year-over-year to -$30857.0; the TTM figure through Mar 2026 stood at $305382.0 (up 113.5% YoY), while the FY2025 annual figure was -$26477.0, changed N/A from the prior year.
- Change in Accured Expenses was -$30857.0 for Q1 2026 at Lunai Bioworks, down from $88541.0 in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $2.2 million in Q1 2024 to a low of -$2.2 million in Q2 2024.
- Historically, Change in Accured Expenses has averaged $13095.6 across 5 years, with a median of -$18520.0 in 2022.
- The sharpest annual moves came in 2024 and 2026: Change in Accured Expenses jumped 671.82% in 2024, then tumbled 3085800.0% in 2026.
- A 5-year view of Change in Accured Expenses shows it stood at -$18520.0 in 2022, then slumped by 59.67% to -$29571.0 in 2023, then sank by 290.01% to -$115329.0 in 2024, then surged by 176.77% to $88541.0 in 2025, then plunged by 134.85% to -$30857.0 in 2026.
- The last three Change in Accured Expenses figures came in at -$30857.0 (Q1 2026), $88541.0 (Q4 2025), and $205738.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 931,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 70.50 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Lunai Bioworks | 95.85 Mn | 92.70 Mn | 20,942.00 | -30,857.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -30,857.00 |
| Mar 31, 2026 | -30,857.00 |
| Dec 31, 2025 | 88,541.00 |
| Dec 31, 2025 | 88,541.00 |
| Sep 30, 2025 | 205,738.00 |
| Sep 30, 2025 | 205,738.00 |
| Jun 30, 2025 | 41,960.00 |
| Jun 30, 2025 | 41,960.00 |
| Mar 31, 2025 | 1.00 |
| Mar 31, 2025 | 1.00 |
| Dec 31, 2024 | -115,329.00 |
| Dec 31, 2024 | -115,329.00 |
| Sep 30, 2024 | 46,891.00 |
| Sep 30, 2024 | 46,891.00 |
| Jun 30, 2024 | -2.19 Mn |
| Jun 30, 2024 | -2.19 Mn |
| Mar 31, 2024 | 2.22 Mn |
| Mar 31, 2024 | 2.22 Mn |
| Dec 31, 2023 | -29,571.00 |
| Dec 31, 2023 | -29,571.00 |